WASHINGTON — U.S. Department of Veterans Affairs (VA) researchers and Veteran volunteers from the Atlanta and San Antonio VA medical centers were part of a recently published study that yielded crucial insights into COVID-19 treatment.
The study published Dec. 11, 2020, by the New England Journal of Medicine, showed the drugs baricitinib and remdesivir combined were far better at improving and reducing recovery time of COVID-19 patients than treatment with remdesivir alone.
“Safe and effective vaccines for COVID-19 are being rolled out in VA and other health care settings, but finding treatments remains crucial,” said VA Secretary Robert Wilkie. “VA researchers and all the Veterans who volunteer for studies are contributing to steady progress with regard to both vaccines and treatment options.”
The combined use of baricitinib, an anti-inflammatory drug, and remdesivir, an antiviral drug, has already influenced clinical practice. On Nov. 19, 2020, the Food and Drug Administration issued an emergency use authorization of the treatment in certain hospitalized adults and children, based mainly on the trial results.
The initial idea for the National Institute of Allergy and Infectious Diseases (NIAID)-sponsored trial was advanced, in part, by a research team at the Atlanta VA Medical Center (VAMC). They had been studying baricitinib prior to the pandemic as a potential agent against other infectious diseases.
Among other studies on the drug, the Atlanta VA team reviewed the medical records of 15 patients with moderate to severe COVID-19 who had received daily doses of baricitinib in addition to other treatment. The addition of the drug was associated with recovery in 11 of the patients.
The results appeared June 2020 in the journal Clinical Infectious Diseases. The researchers interpreted the results cautiously, since the study was based on a small number of patients and was not a randomized, placebo-controlled trial. Nonetheless, the results helped lay the groundwork for the large NIAID-sponsored study that followed.
Learn more about VA studies on COVID-19.
###
Reporters and media outlets with questions or comments should contact the Office of Media Relations at vapublicaffairs@va.gov
Veterans with questions about their health care and benefits (including GI Bill). Questions, updates and documents can be submitted online.
Veterans can also use our chatbot to get information about VA benefits and services. The chatbot won’t connect you with a person, but it can show you where to go on VA.gov to find answers to some common questions.
Subscribe today to receive these news releases in your inbox.
More from the Press Room
News Releases
As a part of the Biden Cancer Moonshot, the Department of Veterans Affairs is expanding its Close to Me cancer care program.
News Releases
The Department of Veterans Affairs posted a final rule amending its regulations regarding character of discharge determinations, expanding access to VA care and benefits for some former service members discharged under other than honorable conditions or by special court-martial.
News Releases
The Department of Veterans Affairs and Department of Defense expanded their existing partnership to allow Veterans, soldiers, cadets, and other beneficiaries to receive care from the Keller Army Community Hospital (KACH) on the West Point Army Installation and at the VA Hudson Valley Health Care System.
